SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03108521

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Sichuan Provincial People's Hospital

With the development of pharmacogenomics and pharmacogenetics, personalized medicine based on genetic are increasingly required clinically. Incretin-based therapy is currently the most popular diabetes treatment. This study mainly research the correlation of incretin-related gene polymorphism and individual differences in the response of these drugs from the following four aspects. 1. . To study Chinese human gene polymorphism's mutation frequency and allele frequency, by screening Chinese people gene polymorphisms which affecting DPP-4 enzymatic activity. 2. . To study the mutation frequency of DPP-4 mutation site(rs12469968, rs3788979, rs2284872, rs7565794) and GLP1R mutation site(rs3765467) in Chinese population. 3. . By collecting clinical parameters and efficacy indicators to reveal the relationship between Chinese DPP-4 gene and GLP1R gene polymorphism on the clinical manifestations and drug response. This study will be improved based on actual experimental research methods, and design intervening measures for Chinese people, to explore the dose-effect relationship of DPP-4 and GLP1R gene polymorphism in the treatment of diabetes in Chinese population. 4. . Incretins is a new generation hypoglycemic agent. By studying gene polymorphism and drug response, to research how to plan treatment for clinical diabetes with DPP-4 and GLP1R gene polymorphism. Provide the basis for individualized treatment of these drugs.

NCT03108521 Diabetes Mellitus
MeSH: Diabetes Mellitus
HPO: Diabetes mellitus

2 Interventions

Name: Sitagliptin

Description: Januvia

Type: Drug

Sitagliptin group

Name: Liraglutide

Type: Drug

Liraglutide group


Primary Outcomes

Measure: Glycated albumin

Time: Change from Baseline Glycated albumin at 4 weeks (Liraglutide group)

Description: 28 SNP genetic points of DPP-4 and GLP1R

Measure: SNP mutation type

Time: Baseline

Measure: Glycosylated hemoglobin (HbA1c)

Time: Change from Baseline HbA1c at 12 weeks (Sitagliptin group)

Measure: Blood glucose

Time: Change from fasting, 0.5h, 2h,3h after take 75g glucose orally of Baseline Blood Glucose at 12weeks (Sitagliptin group) or 4 weeks (Liraglutide group)

Measure: Insulin

Time: Change from fasting and after take 75g glucose orally 0.5h, 2h,3h of Baseline Blood Insulin at 12weeks (Sitagliptin group) or 4 weeks (Liraglutide group)

Measure: C-peptide

Time: Change from fasting and 2h after take 75g glucose orally of Baseline C-peptide at 12weeks (Sitagliptin group) or 4 weeks (Liraglutide group)

Secondary Outcomes

Measure: Total cholesterol

Time: Change from Baseline Total cholesterol at 12 weeks (Sitagliptin group) or 4 weeks (Liraglutide group)

Measure: Triglyceride

Time: Change from Baseline Triglyceride at 12 weeks (Sitagliptin group) or 4 weeks (Liraglutide group)

Measure: Low density lipoprotein

Time: Change from Baseline Low density lipoprotein at 12 weeks (Sitagliptin group) or 4 weeks (Liraglutide group)

Purpose: Treatment

Allocation: Randomized

Single Group Assignment


There are 5 SNPs

SNPs


1 rs12469968

To study the mutation frequency of DPP-4 mutation site(rs12469968, rs3788979, rs2284872, rs7565794) and GLP1R mutation site(rs3765467) in Chinese population.


2 rs2284872

To study the mutation frequency of DPP-4 mutation site(rs12469968, rs3788979, rs2284872, rs7565794) and GLP1R mutation site(rs3765467) in Chinese population.


3 rs3765467

To study the mutation frequency of DPP-4 mutation site(rs12469968, rs3788979, rs2284872, rs7565794) and GLP1R mutation site(rs3765467) in Chinese population.


4 rs3788979

To study the mutation frequency of DPP-4 mutation site(rs12469968, rs3788979, rs2284872, rs7565794) and GLP1R mutation site(rs3765467) in Chinese population.


5 rs7565794

To study the mutation frequency of DPP-4 mutation site(rs12469968, rs3788979, rs2284872, rs7565794) and GLP1R mutation site(rs3765467) in Chinese population.



HPO Nodes


HPO:
Diabetes mellitus
Genes 326
SOX2 MKRN3 SOX3 MKKS SNORD115-1 SPATA7 CDKN2A HFE CERKL UBR1 PRPF31 LRAT PRSS1 TREX1 PRSS2 IFT140 ARL2BP GLRX5 SLC29A3 MAK AHI1 ABCA4 PDE4D ZBTB20 PDE6A PDE6G ZMPSTE24 IMPDH1 CEL STUB1 SPINK1 RTEL1 PDE6B LEMD3 INS HLA-DQB1 GJB4 IFT172 AMACR KIZ CDHR1 HLA-DRB1 CYP19A1 CFTR DHX38 MAFA GAS1 INSR ZFP57 MC4R GATA3 CTRC GATA6 PDX1 IPW PEX1 BBS1 PWRN1 PEX6 BBS2 DNAJC21 PEX10 CDH23 SRP54 DHDDS NDN PRPF6 GCK NDP KCTD1 AGBL5 GPR101 PTCH1 HNF4A ADAR TTPA TUB SNORD116-1 HESX1 STAT1 STAT3 TULP1 BLK BLM ARL6 IFIH1 TTC8 GJA1 PROM1 NEK2 GJB3 SAG FBN1 NEUROD1 SARS2 PNPLA6 BRCA1 ALMS1 BRAF BRCA2 PROKR2 CLCNKB TINF2 KLHL7 REEP6 FAM161A PIK3R1 GLI2 ABCC8 KCNJ11 RNASEH2C ARNT2 NPAP1 SCAPER FSCN2 DCAF17 AHR PRCD DKC1 FGF8 PLAGL1 AKT2 NOP10 FGFR1 PLCD1 GNAS PWAR1 SEMA4A HERC2 MERTK FOXH1 PLIN1 HYMAI NODAL USH2A CLRN1 CNGB1 CNGA1 EIF2AK3 MOG CDON CA4 IMPG2 PDE11A FOXP3 FOXC2 HJV PROK2 RNASEH2B KRAS TCF4 KLF11 EFL1 HNF1A BEST1 HNF1B PNPLA2 NR2E3 MAGEL2 POC1A OFD1 SLC25A4 USB1 NRL CLIP2 APOA5 CISD2 RNASEH2A CTC1 PTF1A WFS1 GPR35 POLD1 FOS RRM2B POLG AGPAT2 RBP3 WRN SLC19A2 HGSNAT GLIS3 SHH AIRE KIAA1549 FUZ BAZ1B RDH12 POMGNT1 PRPH2 ARHGEF18 DNM1L CP TWNK CPA1 CASR PCARE SAMHD1 TDGF1 AIP CAV1 PSTPIP1 FXN APOE IDH3B PPARG RFC2 XRCC4 WRAP53 SIX3 GTF2IRD1 NSMCE2 PRPF8 DLL1 NHP2 TERC TERT EDA RGR SLC7A14 AR LEP OPA1 LEPR PALB2 POLR3A RHO CRB1 ZIC2 MKRN3-AS1 CRX RLBP1 TTC7A PPP1R3A CNBP MST1 ERGIC1 LHX1 TGIF1 USP8 MLXIPL LIG4 LIMK1 EYS ARL3 LIPE OTX2 IGF1R GTF2I HMGA2 ATP6 TRNC SLC12A3 LMNA COX1 COX2 COX3 GUCA1B IFT88 CYTB SLC16A2 PRPF4 PRPF3 ELMO2 PDE8B VANGL1 SBDS EIF2S3 IER3IP1 ZNF408 CIDEC ND1 ARMC5 ND4 ND5 ND6 PRKACA PRKAR1A NKX2-5 APPL1 TRNE TRNF ROM1 ZFYVE26 PARN CAVIN1 BSCL2 TRNH RP9 RP1 ELN TRNK PAX4 RP2 TRNL1 RPGR ATM HAMP CTNS CTNNB1 C8ORF37 TRNQ TRNS1 TRNS2 POLG2 TRNV TOPORS TRNW KDSR HBB SUFU IL2RA RPE65 DNAJC3 SNRNP200 SNRPN PALLD TBL2 DISP1 EDA2R NEUROG3 TP53 CEP19 SMAD4 PCNT ZNF513